American Century Companies Inc. Has $567,000 Holdings in Organogenesis $ORGO

American Century Companies Inc. boosted its stake in shares of Organogenesis (NASDAQ:ORGO) by 32.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 131,220 shares of the company’s stock after buying an additional 32,328 shares during the quarter. American Century Companies Inc. owned approximately 0.10% of Organogenesis worth $567,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Soleus Capital Management L.P. lifted its position in shares of Organogenesis by 5.4% in the 4th quarter. Soleus Capital Management L.P. now owns 12,484,876 shares of the company’s stock worth $39,952,000 after purchasing an additional 645,000 shares during the period. Vanguard Group Inc. lifted its holdings in Organogenesis by 23.4% in the first quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company’s stock valued at $19,144,000 after buying an additional 841,618 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Organogenesis by 18.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,789,265 shares of the company’s stock valued at $8,925,000 after purchasing an additional 442,772 shares during the period. Invesco Ltd. lifted its stake in Organogenesis by 779.7% in the first quarter. Invesco Ltd. now owns 1,069,252 shares of the company’s stock valued at $4,619,000 after buying an additional 947,705 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Organogenesis by 45.3% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 667,529 shares of the company’s stock worth $2,884,000 after purchasing an additional 208,038 shares during the last quarter. 49.57% of the stock is owned by institutional investors and hedge funds.

Organogenesis Price Performance

Shares of ORGO stock opened at $5.00 on Friday. The stock has a market capitalization of $634.30 million, a PE ratio of -35.71 and a beta of 1.75. Organogenesis has a 1-year low of $2.45 and a 1-year high of $6.71. The business has a 50-day moving average of $4.62 and a 200 day moving average of $4.22.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.08). Organogenesis had a negative return on equity of 0.37% and a negative net margin of 1.92%.The business had revenue of $101.01 million during the quarter, compared to analysts’ expectations of $104.75 million. Organogenesis has set its FY 2025 guidance at EPS. Analysts anticipate that Organogenesis will post -0.07 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ORGO. Cantor Fitzgerald increased their target price on shares of Organogenesis from $7.00 to $9.00 and gave the company an “overweight” rating in a report on Friday, August 8th. BTIG Research reiterated a “buy” rating on shares of Organogenesis in a research note on Tuesday, July 15th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Organogenesis currently has a consensus rating of “Moderate Buy” and an average target price of $7.50.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.